- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06388772
Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
April 25, 2024 updated by: Changzhou Qianhong Bio-pharma Co., Ltd.
Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single Doses
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Eight dose groups were initially set up.
The experimental groups were increased from low to high dose according to the principle of increasing dose, and Placebo was added as the control group.
All the selected subjects in the experimental group were given the drug once.
Study Type
Interventional
Enrollment (Actual)
74
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Nanjing Drum Tower Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male or female subjects, male and female equally;
- Aged between 18 and 50 at the time of screening (including boundary values); Male weight ≥50.0kg, female weight ≥45.0kg; All subjects had a body mass index (BMI) between 19 and 28kg/m2 (including boundary values);
- Participate voluntarily and sign informed consent to complete the experiment according to the research protocol.
Exclusion Criteria:
Subjects who meet one of the following conditions will not be enrolled in the trial:
- a person who is allergic to, or is allergic to, 2 or more drugs or foods, or is known to have a history of allergy to the test preparation and any of its components or related preparations;
- Patients with a history of clinically serious diseases such as nervous system, blood circulatory system, digestive system, urinary system, respiratory system, immune system, endocrine system, malignant tumor, mental and metabolic abnormalities, or any clinically significant diseases judged by researchers to be in an active period or unstable state;
- Based on vital signs (including sitting blood pressure, pulse, and body temperature), physical examination, 12-lead electrocardiogram examination, and laboratory examination (including routine blood routine, urine routine, blood biochemistry, and coagulation function), the investigator determined that the abnormality was clinically significant;
- postural hypotension;
- α1-antitrypsin deficiency;
- Patients with difficulty in venous blood collection;
- People with a history of fainting needles and fainting blood;
- A history of drug abuse within the last two years (including repeated and heavy use of various narcotic drugs and psychotropic substances for non-medical purposes);
- Excessive smoking within 3 months before screening (average > 5 cigarettes/day) or unable to stop using any tobacco products during the test period or smokers within 48 hours before screening;
- Excessive daily consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 1 cup =250mL) in the 3 months before screening;
- alcoholics (i.e. men drinking more than 28 standard units per week, women drinking more than 21 standard units per week, 1 standard unit containing 14g of alcohol, such as 360mL beer or 45mL spirits with 40% alcohol or 150mL wine) or regular drinkers (i.e. more than 14 standard units per week) in the six months prior to screening;
- Positive alcohol breath test (test result greater than 0.0mg/100mL);
- Hepatitis B surface antigen (HBsAg), hepatitis C virus(HCV) antibody, syphilis antibody and human immunodeficiency virus(HIV) antibody test one or more positive;
- Positive urine screening for drug abuse (including morphine, methamphetamine, ketamine, dimethylene dioxyamphetamine, tetrahydrocannabinol, cocaine);
- Abnormal chest X-ray or CT findings with clinical significance;
- Abdominal B-ultrasonography (liver, bile, pancreas, spleen and kidney) with abnormal results and clinical significance;
- Severe acute bacterial, viral or fungal infection within 4 weeks prior to screening;
- Patients who had used any protease drugs (such as chylase, indinavir sulfate, ritonavir, bortezomib, isazzomib citrate, etc.) within 4 weeks before screening;
- Use of any prescription or over-the-counter drugs, as well as any functional vitamins or Chinese herbal products within 2 weeks prior to screening;
- Blood donation or blood loss greater than 400mL within 3 months before screening (except physiological blood loss);
- Vaccinated within 1 month before screening, or planned to be vaccinated during the study period and within 1 month after the study ends;
- Those who had undergone surgery within 3 months prior to screening or planned to undergo surgery during the trial;
- Participants who participated in any drug clinical trial as a subject within 3 months before enrollment;
- have consumed a special diet (including grapefruit, chocolate, tea, cola, or any food or beverage containing caffeine, alcoholic beverage, or other food or beverage that affects the absorption, distribution, metabolism, or excretion of drugs) in the 48 hours prior to screening;
- The subjects or their partners do not wish to use one or more non-drug contraceptive methods (such as total abstinence, condoms, Icontraceptive rings, ligation, etc.) for contraception during the trial period or have pregnancy plans within 3 months after the end of the study; Or screening women with positive pregnancy tests or breastfeeding women;
- With magnetic resonance examination contraindications: metal implant, claustrophobia, etc.;
- Other situations in which the investigator considers that participation in the trial may not be appropriate. -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part-A SAD in healthy subjects(Cohort 1-8)
A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects.
Subjects will receive QHRD106 by intramuscular-injection (im).
|
250IU~8400IU,pegylated(PEG)-tissue kallikrein-1
Other Names:
|
Experimental: Part-B Healthy subjects SAD placebo
A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects.
Subjects will receive placebo by intramuscular-injection (im).
|
placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by incidence, severity, and causality of adverse events
Time Frame: Up to 36 days after final dose
|
The frequency and number of adverse events, adverse reactions and serious adverse
|
Up to 36 days after final dose
|
Plasma measurements of QHRD106
Time Frame: Up to 36 days after final dose
|
The concentration of a single dose was measured at 8 different doses
|
Up to 36 days after final dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Juan Li, Doctor, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 5, 2021
Primary Completion (Actual)
July 22, 2022
Study Completion (Actual)
January 6, 2023
Study Registration Dates
First Submitted
April 25, 2024
First Submitted That Met QC Criteria
April 25, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 25, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HJG-CZQH-QHRD106
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Anaconda Biomed S.L.Not yet recruitingAcute Ischemic Stroke From Large Vessel Occlusion
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States